Literature DB >> 8274912

Acromegaly: treatment after 100 years.

J A Wass.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8274912      PMCID： PMC1679591          DOI： 10.1136/bmj.307.6918.1505

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  18 in total

Review 1.  Radiation oncogenesis in relation to the treatment of pituitary tumours.

Authors:  A Jones
Journal:  Clin Endocrinol (Oxf)       Date:  1991-11       Impact factor: 3.478

Review 2.  The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors.

Authors:  S W Lamberts
Journal:  Endocr Rev       Date:  1988-11       Impact factor: 19.871

Review 3.  The treatment of acromegaly.

Authors:  J A Wass; E R Laws; R V Randall; G E Sheline
Journal:  Clin Endocrinol Metab       Date:  1986-08

4.  Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma.

Authors:  M Brada; D Ford; S Ashley; J M Bliss; S Crowley; M Mason; B Rajan; D Traish
Journal:  BMJ       Date:  1992-05-23

Review 5.  Gallstones during octreotide therapy.

Authors:  R H Dowling; S H Hussaini; G M Murphy; G M Besser; J A Wass
Journal:  Metabolism       Date:  1992-09       Impact factor: 8.694

Review 6.  Surgical management of acromegaly.

Authors:  R Fahlbusch; J Honegger; M Buchfelder
Journal:  Endocrinol Metab Clin North Am       Date:  1992-09       Impact factor: 4.741

Review 7.  Clinical manifestations of acromegaly.

Authors:  M E Molitch
Journal:  Endocrinol Metab Clin North Am       Date:  1992-09       Impact factor: 4.741

Review 8.  Radiation therapy of acromegaly.

Authors:  R C Eastman; P Gorden; E Glatstein; J Roth
Journal:  Endocrinol Metab Clin North Am       Date:  1992-09       Impact factor: 4.741

9.  Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.

Authors:  A L Barkan; R P Kelch; N J Hopwood; I Z Beitins
Journal:  J Clin Endocrinol Metab       Date:  1988-01       Impact factor: 5.958

10.  Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase.

Authors:  A Spada; M Arosio; D Bochicchio; N Bazzoni; L Vallar; M Bassetti; G Faglia
Journal:  J Clin Endocrinol Metab       Date:  1990-12       Impact factor: 5.958
View more
  4 in total

1.  Endoscopic endonasal transsphenoidal approach: an additional reason in support of surgery in the management of pituitary lesions.

Authors:  P Cappabianca; A Alfieri; A Colao; D Ferone; G Lombardi; E de Divitiis
Journal:  Skull Base Surg       Date:  1999

Review 2.  Growth hormone pulsatility in acromegaly following radiotherapy.

Authors:  S R Peacey; S M Shalet
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

3.  Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients.

Authors:  P Marzullo; D Ferone; C Di Somma; R Pivonello; M Filippella; G Lombardi; A Colao
Journal:  Pituitary       Date:  1999       Impact factor: 4.107

4.  The treatment of de novo acromegalic patients with octreotide-LAR: efficacy, tolerability and cardiovascular effects.

Authors:  J Gilbert; M Ketchen; P Kane; T Mason; E Baister; M Monaghan; S Barr; P E Harris
Journal:  Pituitary       Date:  2003       Impact factor: 4.107
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.